H.C. Wainwright raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $22 from $19 and keeps a Buy rating on the shares following the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics Reports Strong Q2 2025 Growth
- Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating
- Arcutis Biotherapeutics reports Q2 EPS (13c), consensus (16c)
- Carvana upgraded, Ulta Beauty downgraded: Wall Street’s top analyst calls
- Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs